Chart, page-197

recieved this email from Auscann and they are going to get approval for growing in Australia bases on ZLD therapeutics .They are meeting are the requirements to get the approval from Authroties. So good news will be soon


In Australia we are growing from clonal material not seed. This genetic material will be imported in from our Spanish Phytoplant Research SL and Canadian Canopy Growth Corp partners once we have our cultivation permit. This is issued after granting of the licence and a site inspection. This is expected to occur around mid 2017. These genetics will undergo quarantine prior to being imported. We need to use clonal material as there is too much variability using seed for production of standardise medicines.
3. I note that our cultivation in Chile was done last week using seed imported from the Netherlands. We will use our clonal material for future plantings in Chile. For our 2017 buyers in Chile the use of seed is acceptable for the formulations they require.
4. We will be importing medicines from our partner Canopy in early 2017 for supplying clinicians prescribing to their patients and for clinical studies. We will be supplying epilepsy and chronic pain studies in WA and NSW. One clinical trial group that we are supplying is Zelda Therapeutics. They are a customer of AusCann’s and we supply all of their formulations. Once we have Australian product (expected around end of 2017) we will replace the Canadian product with this.